Role of the angiotensin II type-2 receptor in radiation nephropathy

Translational Research

Volumn 150, Issue 2, 2007, Pages 106-115

  Cohen, Eric P ^a   Fish, Brian L ^a   Sharma, Mukut ^a   Li, X Allen ^a   Moulder, John E ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR UPREGULATION; REPRODUCIBILITY; TREATMENT OUTCOME;

EID: 34447542611     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2007.03.004     Document Type: Article

References (43)

1. Kal H.B., and van Kempen-Harteveld M.L. Renal dysfunction after total body irradiation: dose-effect relationship. Int J Radiat Oncol Biol Phys 65 (2006) 1228-1232
2. Cohen E.P., and Robbins M.E.C. Radiation nephropathy. Semin Nephrol 23 (2003) 486-499
3. Zenz T., Schlenk R.F., Glatting G., Neumaier B., Blumstein N., Buchmann I., et al. Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation. J Nucl Med 47 (2006) 278-286
4. Lambert B., Cybulla M., Weiner S.M., Van De Wiele C., Ham H., Dierckx R.A., et al. Renal toxicity after radionuclide therapy. Radiat Res 161 (2004) 607-611
5. Moulder J.E., Fish B.L., and Cohen E.P. ACE inhibitors and AII receptor antagonists in the treatment and prevention of bone marrow transplant nephropathy. Curr Pharm Des 9 (2003) 737-749
6. Oikawa T., Freeman M., Lo W., Vaughan D.E., and Fogo A. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 51 (1997) 164-172
7. Juncos L.I., Carrasco Dueñas S., Cornejo J.C., Broglia C.A., and Cejas H. Long-term enalapril and hydrochlorothiazide in radiation nephritis. Nephron 64 (1993) 249-255
8. Cohen E.P., Hussain S., and Moulder J.E. Successful treatment of radiation nephropathy with angiotensin II blockade. Int J Radiat Oncol Biol Phys 55 (2003) 190-193
9. Moulder J.E., and Cohen E.P. Future strategies for mitigation and treatment of chronic radiation-induced normal tissue injury. Semin Radiat Oncol 17 (2007) 141-148
10. Cohen E.P., Fish B.L., and Moulder J.E. Angiotensin II infusion exacerbates radiation nephropathy. J Lab Clin Med 134 (1999) 283-291
11. 2 receptor in the kidney: role in health and disease. Semin Nephrol 24 (2004) 93-00
12. Moulder J.E., Fish B.L., and Cohen E.P. Impact of angiotensin II type 2 receptor blockade on experimental radiation nephropathy. Radiat Res 161 (2004) 312-317
13. Moulder JE, Fish BL, Cohen EP. Treatment of radiation nephropathy with ACE inhibitors and AII type-1 and type-2 receptor antagonists. Curr Pharm Des. In press.
14. Cao Z., Bonnet F., Candido R., Nesteroff S.P., Burns W.C., Kawachi H., et al. Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Amer Soc Nephrol 13 (2002) 1773-1787
15. Moulder J.E., and Fish B.L. Late toxicity of total body irradiation with bone marrow transplantation in a rat model. Int J Radiat Oncol Biol Phys 16 (1989) 1501-1509
16. Moulder J.E., Cohen E.P., Fish B.L., and Hill P. Prophylaxis of bone marrow transplant nephropathy with captopril, an inhibitor of angiotensin-converting enzyme. Radiat Res 136 (1993) 404-407
17. Cohen E.P., Fish B.L., and Moulder J.E. The renin-angiotensin system in experimental radiation nephropathy. J Lab Clin Med 139 (2002) 251-257
18. Ma C.M., Coffey C.W., DeWerd L.A., Liu C., Nath R., Seltzer S.M., et al. AAPM protocol for 40-300 kV x-ray beam dosimetry in radiotherapy and radiobiology. Med Phys 28 (2001) 868-893
19. 1 receptors. J Biol Chem 271 (1996) 22719-22735
20. Siegl P.K.S., Chang R.S.L., Mantlo N.B., Chakavarty P.K., Ondeyka D.L., Greenlee W.J., et al. In vivo pharmacology of L-158,809, a highly potent and selective non-peptide angiotensin II receptor blocker. J Pharmacol Exper Ther 262 (1992) 139-144
21. Chang R.S.L., Siegl P.K.S., Clineschmidt B.V., Mantlo N.B., Chakavarty P.K., Greenlee W.J., et al. In vitro pharmacology of L-158,809, a new and highly potent and selective angiotensin II receptor antagonist. J Pharmacol Exper Ther 262 (1992) 133-138
22. 2 receptor ligands CGP 42112B and PD 123319 in the sodium-depleted rat. Europ J Pharm 249 (1993) 85-93
23. Cohen E.P., Fish B.L., and Moulder J.E. Successful brief captopril treatment in radiation nephropathy. J Lab Clin Med 129 (1997) 536-547
24. Moulder J.E., Fish B.L., and Cohen E.P. Brief pharmacologic intervention in experimental radiation nephropathy. Radiat Res 150 (1998) 535-541
25. Stone H.B., Moulder J.E., Coleman C.N., Ang K.K., Anscher M.S., Barcellos-Hoff M.H., et al. Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI workshop, December 3-4, 2003. Radiat Res 162 (2004) 711-728
26. Ernsberger P., Zhou J., Damon T.H., and Douglas J.G. Angiotensin II receptor subtypes in cultured rat renal mesangial cells. Amer J Physiol 263 (1992) F411-F416
27. Macari D., Whitebread S., Cumin F., DeGasparo M., and Levens N. Renal actions of the angiotensin AT receptors ligands CGP-42112 and PD-123319 after blockade of the renin-angiotensin system. Europ J Pharm 259 (1994) 27-36
28. Lee E.T., and Desu M.M. A computer program for comparing K samples with right-censored data. Comput Programs Biomed 2 (1972) 315-321
29. Bottari S.P., de Gasparo M., Steckelings U.M., and Levens N.R. Angiotensin II receptor subtypes: characterization, signalling mechanisms, and possible physiological implications. Front Neuroendocrinol 14 (1993) 123-171
30. Wolf G. "The road not taken": role of angiotensin II type 2 receptor in pathophysiology. Nephrol Dial Trans 17 (2002) 195-198
31. Fujihara C.K., Velho M., Malheiros D.M.A.C., and Zatz R. An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney Int 67 (2005) 1913-1924
32. 1 receptor-activated signaling mediates angiotensin IV-induced renal cortical vasoconstriction in rats. Amer J Physiol 290 (2006) F1024-F1033
33. 4-receptor system in the rat kidney. Amer J Physiol 274 (1998) F290-F299
34. Sechi L.A., Grady E.F., Griffin C.A., Kalinyak J.E., and Schambelan M. Distribution of angiotensin II receptor subtypes in rat and human kidney. Amer J Physiol 262 (1992) F236-F240
35. 2 receptor mRNA expression and renal vasodilatation are increased in renal failure. Hypertension 38 (2001) 669-673
36. Navar L.G., Lewis L., Hymel A., Braam B., and Mitchell K.D. Tubular fluid concentrations and kidney contents of angiotensins I and II in anesthetized rats. J Amer Soc Nephrol 5 (1994) 1153-1158
37. Wong P.C., Christ D.D., and Timmermans P.B.M.W.M. Enhancement of losartan (DuP 753)-induced angiotensin II receptor antagonism by PD123177 in rats. Europ J Pharm 220 (1992) 267-270
38. Jaggi J.S., Seshan S.V., McDevitt M.R., Sgouros G., Hyjek E., and Scheinberg D.A. Mitigation of radiation nephropathy after internal α-particle irradiation of kidneys. Int J Radiat Oncol Biol Phys 64 (2006) 1503-1512
39. Brown N.J., Nakamura S., Ma L., Nakamura I., Donnert E., Freeman M., et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 58 (2000) 1219-1227
40. Tanabe A., Naruse M., Arai K., Naruse K., Yoshimoto T., Seki T., et al. Angiotensin II stimulates both aldosterone secretion and DNA synthesis via type 1 but not type 2 receptors in bovine adrenocortical cells. J Endocrinol Invest 21 (1998) 668-672
41. 2 receptors mediate tonic renal medullary vasoconstriction in renovascular hypertension. Br J Pharm 144 (2005) 486-492
42. Cohen EP, Joines MM, Moulder JE. Prevention and treatment of radiation injuries-The role of the renin-angiotensin system. In: Rubin P, Constine LS, Mark LB, Okunieff P, eds. Late Effects on Normal Tissues of Cancer Treatment. Heidelberg, Germany: Springer-Verlag. In press.
43. Kobori H., Ozawa Y., Suzaki Y., Prieto-Carrasquero M.C., Nishiyama A., Shoji T., et al. Intratubular angiotensinogen in hypertension and kidney diseases. Am J Hyperten 19 (2006) 541-550